EP3552603C0 - UNIT DOSES, AEROSOLS, KITS AND METHODS FOR THE TREATMENT OF HEART DISEASES BY PULMONARY DELIVERY - Google Patents

UNIT DOSES, AEROSOLS, KITS AND METHODS FOR THE TREATMENT OF HEART DISEASES BY PULMONARY DELIVERY

Info

Publication number
EP3552603C0
EP3552603C0 EP19176305.1A EP19176305A EP3552603C0 EP 3552603 C0 EP3552603 C0 EP 3552603C0 EP 19176305 A EP19176305 A EP 19176305A EP 3552603 C0 EP3552603 C0 EP 3552603C0
Authority
EP
European Patent Office
Prior art keywords
aerosols
kits
treatment
methods
unit doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19176305.1A
Other languages
German (de)
French (fr)
Other versions
EP3552603B1 (en
EP3552603A1 (en
Inventor
Carlos A Schuler
Rangachari Narasimhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incarda Therapeutics Inc
Original Assignee
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incarda Therapeutics Inc filed Critical Incarda Therapeutics Inc
Publication of EP3552603A1 publication Critical patent/EP3552603A1/en
Application granted granted Critical
Publication of EP3552603B1 publication Critical patent/EP3552603B1/en
Publication of EP3552603C0 publication Critical patent/EP3552603C0/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19176305.1A 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Active EP3552603B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
EP10754091.6A EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
PCT/US2010/027740 WO2010107964A1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP10754091.6A Division EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP10754091.6A Division-Into EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (3)

Publication Number Publication Date
EP3552603A1 EP3552603A1 (en) 2019-10-16
EP3552603B1 EP3552603B1 (en) 2024-11-06
EP3552603C0 true EP3552603C0 (en) 2024-11-06

Family

ID=42739985

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19176272.3A Active EP3552602B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP10754091.6A Active EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP19176305.1A Active EP3552603B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP19176272.3A Active EP3552602B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP10754091.6A Active EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Country Status (9)

Country Link
US (5) US8974828B2 (en)
EP (3) EP3552602B1 (en)
JP (5) JP2012520890A (en)
AU (1) AU2010226613B2 (en)
CA (2) CA2835771C (en)
DK (1) DK2413902T3 (en)
ES (3) ES2750359T3 (en)
PL (1) PL2413902T3 (en)
WO (1) WO2010107964A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750359T3 (en) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Unit doses, sprays, kits, and procedures for treating heart conditions by lung administration
EP2654864B1 (en) 2010-12-22 2020-10-28 Syqe Medical Ltd. System for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
TWI590837B (en) * 2014-03-25 2017-07-11 林信湧 Inhaled pharmaceutical composition for treating heart disease and preparation method thereof
CN106604755B (en) 2014-06-30 2020-08-11 Syqe医药有限公司 Flow-regulated inhaler device
EP3160565B1 (en) * 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
GB2542064B (en) * 2015-01-20 2020-11-18 Univ California Unit aerosol doses for anticoagulation
MD3283067T2 (en) * 2015-04-14 2020-05-31 Milestone Pharmaceuticals Inc Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
ES2874087T3 (en) 2016-01-06 2021-11-04 Syqe Medical Ltd Low-dose therapeutic treatment
CA3012333A1 (en) * 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
WO2018209107A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES3040411T3 (en) * 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
US20210228825A1 (en) * 2018-06-05 2021-07-29 Incarda Therapeutics, Inc. Methods for diagnosing brugada syndrome using an aerosol
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) * 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11007185B2 (en) * 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR102891439B1 (en) * 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. Antiarrhythmic formulation
JP2024502236A (en) * 2020-12-17 2024-01-18 インカーダ セラピューティクス， インコーポレイテッド Kits and methods for induction of cardioversion in subjects with atrial arrhythmia

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (en) 1974-03-18 1977-05-30 Isf Spa INHALER
SE408265B (en) 1975-12-12 1979-06-05 Draco Ab DEVICE FOR CARBON DIOXIDE POWERED ENDOSAEROSOL, INTENDED FOR INHALATION
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (en) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti DEVICE FOR THE QUICK INHALATION OF POWDER DRUGS BY PERSONS SUFFERING FROM ASTHMA
DE3634952A1 (en) 1986-10-14 1988-04-21 Bayer Ag IMIDAZO-PYRROLO-PYRIDINE DERIVATIVES
JP3202705B2 (en) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション Small particles of aerosols of medical liposomes and drug-containing liposomes
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
KR100419037B1 (en) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 Methods of delivery of insulin through the lungs and their composition
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (en) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ Inhalation type dispenser
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ATE287703T1 (en) 1995-04-14 2005-02-15 Nektar Therapeutics POWDERED PHARMACEUTICAL FORMULATIONS WITH IMPROVED DISPERSIBILITY
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
KR100575070B1 (en) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 Stabilized bioactive agents and methods of use thereof
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (en) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
IL143046A0 (en) 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
ATE422924T1 (en) 1999-05-28 2009-03-15 Nektar Therapeutics DEVICE FOR DISPENSING MEASURED QUANTITIES OF AEROSOL CONTAINING MEDICATION
CA2406206C (en) * 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PT1280520E (en) 2000-05-10 2014-12-16 Novartis Ag Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
EP1343372A2 (en) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
BR0208012A (en) 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drugs and one hfa propellant and at least one pharmaceutical composition and inhaler packaged to treat asthma
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
JP4795637B2 (en) * 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド Nose nebulizer
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1515768B1 (en) 2002-05-07 2013-11-06 The State University of New York at Stony Brook Devices for targeted endobronchial therapy
WO2004060351A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US20050009776A1 (en) * 2003-04-24 2005-01-13 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc Treatment of lung diseases and pre-lung disease conditions
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
TWI396541B (en) 2005-10-10 2013-05-21 Boehringer Ingelheim Int Novel combinations of medicaments for the treatment of respiratory diseases
ITMI20051999A1 (en) * 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
EP1951672B1 (en) * 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
CL2007002689A1 (en) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS.
ES2596263T3 (en) 2006-10-25 2017-01-05 Novartis Ag Powder dispersion apparatus
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
TW200840578A (en) 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20110144125A1 (en) 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
US8501727B2 (en) * 2008-08-22 2013-08-06 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
JP5730316B2 (en) * 2008-09-23 2015-06-10 ラボラトリー スキン ケア インコーポレイテッド Method for producing uniform, hard, spherical nanoporous calcium phosphate particles filled with activator
ES2750359T3 (en) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Unit doses, sprays, kits, and procedures for treating heart conditions by lung administration

Also Published As

Publication number Publication date
AU2010226613A1 (en) 2011-09-29
JP2012520890A (en) 2012-09-10
US20190060230A1 (en) 2019-02-28
EP3552603B1 (en) 2024-11-06
US20120003318A1 (en) 2012-01-05
JP2015193657A (en) 2015-11-05
EP3552602A1 (en) 2019-10-16
EP3552602B1 (en) 2025-03-05
CA2755809C (en) 2014-02-18
EP3552603A1 (en) 2019-10-16
ES2750359T3 (en) 2020-03-25
JP2019019139A (en) 2019-02-07
CA2835771A1 (en) 2010-09-23
ES3003038T3 (en) 2025-03-10
US8974828B2 (en) 2015-03-10
CA2755809A1 (en) 2010-09-23
JP7071949B2 (en) 2022-05-19
CA2835771C (en) 2017-01-24
EP3552602C0 (en) 2025-03-05
US20150313842A1 (en) 2015-11-05
ES3036464T3 (en) 2025-09-19
EP2413902A1 (en) 2012-02-08
US10045939B2 (en) 2018-08-14
US20180318213A1 (en) 2018-11-08
JP6715305B2 (en) 2020-07-01
JP2017160268A (en) 2017-09-14
EP2413902A4 (en) 2014-02-19
WO2010107964A1 (en) 2010-09-23
EP2413902B1 (en) 2019-07-17
DK2413902T3 (en) 2019-10-07
PL2413902T3 (en) 2020-01-31
US20180296480A1 (en) 2018-10-18
AU2010226613B2 (en) 2013-07-25
JP2019203032A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EP3552603C0 (en) UNIT DOSES, AEROSOLS, KITS AND METHODS FOR THE TREATMENT OF HEART DISEASES BY PULMONARY DELIVERY
LTC2785706I2 (en) SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-RECEPTOR-RELATED DISEASES
EP2726511A4 (en) COMPOSITIONS, USES THEREOF AND METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
EP2686007A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR MACULOPATHY AND SYMPTOMS THEREOF
EP2723391A4 (en) FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF DISEASES
EP4368228C0 (en) PATIENT INTERFACE SYSTEM FOR THE TREATMENT OF RESPIRATORY DISEASES
EP2773369A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ORAL DISEASES
EP2780472A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BUBBLE CANCER
EP2793932A4 (en) CTP-BASED INSULIN ANALOGUE FOR THE TREATMENT OF DIABETES
EP3494922C0 (en) PROCESSES FOR THE MANUFACTURE OF PARTIAL OR TOTAL DENTURES
PT2528946T (en) METHODS OF TREATMENT OF AUTOIMUNE DISEASES WITH ANTIGONISTS OF DLL4
EP3628326C0 (en) METHODS AND MATERIALS FOR THE TREATMENT OF POMPE DISEASE
EP2470553C0 (en) POLYHYDROYLATED BIL ACID FOR THE TREATMENT OF BILARY DISEASES
EP2579936A4 (en) MAGENSONDE FOR THE TREATMENT OF ADIPOSITAS
PL2717692T3 (en) TETRAHYDROCANNABINOL-11-OWE ACIDS FOR USE IN THE TREATMENT OF FIBERATAL DISEASES
EP2849738C0 (en) HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF LUNG DISEASES
PL2627345T3 (en) Preparations for the treatment of diseases of the upper respiratory tract
IL231217A0 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2544703A4 (en) METHOD FOR THE TREATMENT OF VASCULAR INFLAMMATORY DISEASES
DK2236149T3 (en) Medical composition for the treatment of respiratory infectious diseases
EP3621616A4 (en) UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION
EP2685970C0 (en) COMPOSITION CONTAINING A DIINDOLYLMETHANE AND A RETINOID FOR THE TREATMENT OF SKIN DISEASES
EP2718255A4 (en) CHINONIC COMPOUNDS FOR THE TREATMENT OF APE1-MEDIATED DISEASES
EP2825185C0 (en) NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP2787923A4 (en) DECELLULARIZED COMPOSITE TISSUE BIOUSES FOR THE RECONSTRUCTION OF MUSCLES-TISSUE TISSUE INTERFACES AND METHOD OF MANUFACTURING THEM

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190523

AC Divisional application: reference to earlier application

Ref document number: 2413902

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013847

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200914

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230427

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230711

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240104

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20240604

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NARASIMHAN, RANGACHARI

Inventor name: SCHULER, CARLOS A

AC Divisional application: reference to earlier application

Ref document number: 2413902

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010069567

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20241129

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20241210

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_64614/2024

Effective date: 20241206

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3003038

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250310

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 16

Effective date: 20250219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250219

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250401

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241106

26N No opposition filed

Effective date: 20250807

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251023